CHLORZOXAZONE | A089859 | WATSON LABORATORIES INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Pharmobedient Consulting, LLC FDA-2024-P-2778 · 13 docket documents Pharmobedient Consulting, LLC filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Chlorzoxazone Orally Disintegrating Tablets in 250 mg and 500 mg strengths suitable for submission in an Abbreviated New Drug Applicati | Suitability | 2024-06-11 | Denied | Pharmobedient Consulting, LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.2314
per ea
Lowest NADAC/Unit
$0.2314
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00591252001CHLORZOXAZONE 500 MG TABLET | $0.2314 | EA | Generic | — | 2026-06-17 |
| 00591252005CHLORZOXAZONE 500 MG TABLET | $0.2314 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.